1 / 51

L’HER2-positività: dall’anatamopatologia alla clinica

L’HER2-positività: dall’anatamopatologia alla clinica. Cosa altro è importante sapere oltre l’HER2 status: recettori ormonali, profili di espressione genica…. Stefania Gori Oncologia Medica- Perugia. Prognosis of metastatic breast cancer by HER2 status and trastuzumab treatment. HER2+. 25%.

selma
Télécharger la présentation

L’HER2-positività: dall’anatamopatologia alla clinica

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. L’HER2-positività: dall’anatamopatologia alla clinica Cosa altro è importante sapere oltre l’HER2 status: recettori ormonali, profili di espressione genica… Stefania Gori Oncologia Medica- Perugia

  2. Prognosis of metastatic breast cancer by HER2 status and trastuzumab treatment HER2+ 25% 13% Dawood S, JCO 2010 HER2+ MBC: worse survival

  3. * Statistically significant difference versus CT arm

  4. Time from diagnosis (months) Multivariate model HER2+ and trastuzumab vs HER2-negative HR of death 0.56; 95% CI 0.45-0.69; p< .0001 Multivariate model HER2+ and trastuzumab vs HER2+ no trastuzumab HR of death 045; 95% CI 0.33-0.63; p< .0001 Dawood S, JCO 2010

  5. HER2-positive breast cancer HR status

  6. HER2- HER2- HER2+ HER2+ HER2+ HER2+ * * Time from diagnosis-months Time from diagnosis-months HR-negative HR-positive Overall survival by Trastuzumab treatment group and according to hormone receptor status 5y-OS 5y-OS HER2+ HER2+ HR- 8.9 mo HR+ 14.5 mo HR- and trastuzumab 17.7 mo HR+ and Trastuzumab 29.7 mo

  7. Even in presence of trastuzumab, HR status is still a prognostic factor in MBC Dawood S, JCO 2010

  8. HER2+ and HR+ MBC:Anti-HER2 plus hormonal therapy

  9. 1st line therapy in HR+ and HER2+ MBC Poor PS No/limited visceral metastases Slowly Progression  Expression of HR Good PS Visceral metastases Rapidly progressing Trastuzumab+ Taxane Trastuzumab+ Anastrozole Lapatinib+ Letrozole Lapatinib+ Capecitabine

  10. Neoadjuvant CT in unselected for HER2 status BC Outcome by pCR and HR status .003 <.0001 .002 .04 Guarnieri V, JCO 2006

  11. NEOALTTO1 Phase III NEOSPHERE2 Phase II N=417 N=450 docetaxel + pertuzumab SURGERY FECx3 T L lapatinib FEC X 3 paclitaxel docetaxel + trastuzumab S U R GE R Y FECx3 T T R Operable T >2 cm R Operable or LABC/IBC D  FEC T trastuzumab + pertuzumab trastuzumab paclitaxel L+T docetaxel + trastuzumab +pertuzumab FECx3 T 3 lapatinib 34 wks trastuzumab paclitaxel 52 wks of anti-HER2 52 wks of anti-HER2 + 12 wks 6 wks 1. Baselga J. et al, SABC 2010; 2 Gianni L et al, SABC 2010

  12. NEOALTTO:pCR by Hormone Receptor Status L: lapatinib; T: trastuzumab; L+T: lapatinib plus trastuzumab pCR pathologic complete response HR: hormone receptors

  13. ER or PR pos ER and PR neg NeoSphere: pCR and hormone receptors status 70 60 50 63.2 40 pCR, %  95% CI 30 20 36.8 30.0 29.1 10 26.0 20.0 17.4 5.9 0 TH THP HP TP H, trastuzumab; P, pertuzumab; T, docetaxel 7

  14. Paclitaxel 80 mg/m2 CHERLOB: Study plan   R A N D O M I Z A T I O N A C O R E B I O P S Y S U R G E R Y   B  Lapatinib 1500 mg continuous daily dose (CDD) 121 pts II-IIIA T>2cm   C Lapatinib 1000 mg CDD 5 FU 600 mg/m2 Epi 75 mg/m2 CTX 600 mg/m2  LVEF Trastuzumab 2 mg/kg Guarneri V, ASCO 2011 #507

  15. [TITLE] Guarneri V, ASCO 2011 #507

  16. [TITLE]

  17. HER2- positività: Stato dei Recettori ormonali Setting metastatico Lo stato dei recettori ormonali identifica sottogruppi con diversa prognosi, indipendentemente dal trattamento con trastuzumab Possono essere identicabili , da un punto di vista clinico, sottogruppi di pts HR+ candidabili a terapia di 1a linea con ormonoterapia + agente antiHER2

  18. HER2- positività: Stato dei Recettori ormonali Setting neoadiuvante Predice il tasso di pCR ottenibile con CT+ agenti anti-HER2 pCR % inferiore nei tumori HR+ vs HR-

  19. HER2-positive breast cancer Gene- expression profiling

  20. Luminal A Luminal A Luminal B Luminal B HER2+ HER2+ Basal Basal OSmonths RFSmonths Survival analysis of the 49 breast cancer patients , uniformly treated in a prospective study, based on different gene expression classification Sorlie T, PNAS 2001; 98:10869-10874

  21. Immunohistochemical identification of breast tumour intrinsic subtypes. Carey L A, JAMA 2006; 295: 2492-2502

  22. Cheang MCU, JNCI 2009; 101:736-50 Cheang MCU, JNCI 2009;101:736-50

  23. Survival by 70-gene Mammaprint signature for 89 HER2+ pts who did not receive CT or trastuzumab Knauer M, BJC 2010; 103:1788-93

  24. The 70-gene prognosis signature is an independent prognostic indicator that identifies a subgroup of HER2-positive early BC with a favorable long-term outcome Survival by 70-gene Mammaprint signature for 89 HER2+ pts who did not receive CT or trastuzumab Knauer M, BJC 2010; 103:1788-93

  25. Mechanisms of resistance to trastuzumab Prevention of trastuzumab binding to HER2 Inhibition of immune-mediate mechanisms Upregulation of signaling pathways downstream of HER2 Upregulation of alternative growth factor receptor –signaling pathways

  26. HER2-positive breast cancer p95-HER2 status

  27. p95HER2 is expressed in 30% of HER2+ BC Trastuzumab …by either proteolytic shedding of ECD1 or by alternative initiation of translation of the HER2 mRNA2 p95HER2 1. Codoni-Servat J, Cancer Res 1999;59:1196-201 2. Anido J, EMBO J 2006; 25:3234-44

  28. p95HER2 and Response to Trastuzumab 46 patients with MBC treated with trastuzumab1 1Scaltriti, M JNCI 2007

  29. p95HER2 and Reponse to Trastuzumab 29 patients with EBC treated with neoadj. trastuzumab (CherLob)2 46 patients with MBC treated with trastuzumab1 1Scaltriti, M JNCI 2007 2Guarneri, V et al. ASCO 2011 #507

  30. GeparQuattro:p95HER2 and Response to Trastuzumab(N=145 patients treated with EC+T  Doc+T) P<0.0001 (≤20% strongly positive for 611 CTF) (>20% strongly positive for 611 CTF) Loibl S et al, ASCO 2011 Abstr #530

  31. Cut-off at 80% P= 0.44 60 P= 0.68 54% P= 1 50 40 35.7% 33% 33.3% 30% 30 25% 20 10 p95 +n=2/6 p95 +n=3/9 p95 –n=7/23 p95 +n=3/12 p95 –n=5/14 p95 –n=13/24 0 Arm A (CT + T) Arm B (CT +L) Arm C (CT + T + L) pCR rate according to p95HER2 expression: p95HER2 status does not predict pCR rate following treatment with CT+ trastuzumab or lapatinib or the combination of both In all treatment arms, no significant difference in pCR rates at 80% or other cut-offs evaluated Guarneri V- ASCO 2011 #507

  32. p95HER2 and clinical response to lapatinib (PFS) Results from 68 and 156 MBC pts Lapatinib monotherapy- EGF20009 Lapatinib+ capecitabine- EGF100151 Scaltriti M, Clin Cancer Res 2010

  33. HER2- positività: p95 HER2 Setting metastatico p95HER2+ resistenza al trastuzumab 1 Lapatinib efficace sia nei tumori p95HER2+ che p95HER- 2 Setting neoadiuvante Risultati contrastanti 3-4 1. Scaltriti 2007; 2.Scaltriti 2010; 3.Guarneri ASCO 2011; 4.Lobi ASCO 2011

  34. HER2-positive breast cancer PTEN status

  35. IHC expression of PTEN (a negative regulator of Akt activities) P P P P PI3-K RAS-GTP PTEN PDK1,2 Akt/PKB RAF MEK ERK EGF, TGF-α HER2 EGFR SOS PI(4,5)P2 PI(3,4,5)P3 P RAS-GDP Grb2 GTP PDK1,2 TKI Survival pathway Proliferation pathway

  36. P < 0.001 Nagata Y, Cancer Cell 2004

  37. Background PTEN Impact on Sensitivity or Resistance to Trastuzumab • Preclinical data suggest PTEN loss associated with trastuzumab resistance • O’Brien 2010; Stemke-Hale 2008; Saal 2005; Nagata 2004 • Clinical data available to date: limited and conflicting • PTEN loss associated with trastuzumab resistance • Dave 2011; Esteva 2010 ; Razi SE 2011 • PTEN loss NOT associated with trastuzumab resistance • Fabi 2010; Gori 2009; Yonemori 2009 Perez EA – ASCO 2011

  38. Gori S, et al PTEN status negative (Nagata score <9): 60% (Nagata score <4): 15% PTEN status evaluated by IHC in 45 HER2+ MBC treated with trastuzumab-based therapy was not significantly associated with outcome (ORR, TTP, OS).

  39. Gianni L, ASCO 2008 #504

  40. Background NCCTG N9831 Trial Incorporating Trastuzumab in Adjuvant Therapy Arm A (1232 pts) R A N D O M I Z E AC T HER2 positive (FISH ratio ≥2 or IHC 3+ >10%) Arm B (1216 pts) AC T H Arm C (1057 pts) n=3,505 AC T H = AC (doxorubicin/cyclophosphamide 60/600 mg/m2 q3w × 4) = T (paclitaxel 80 mg/m2/wk × 12) = H (trastuzumab 4 mg/kg loading + 2 mg/kg/wk × 51) Perez EA. Protocol NCCTG-N9831

  41. Conclusions • Data and results were similar across both analyses • In contrast to some preclinical and limited clinical studies, loss of PTEN protein expression was not associated with decreased tumor sensitivity to adjuvant trastuzumab • Data demonstrate benefit of treating HER2+ breast cancer pts with adjuvant trastuzumab regardless of PTEN protein expression status Perez EA, et al. J Clin Oncol 2011; 29(15s)Part I: 631s

  42. HER2- positività: PTEN status Setting metastatico Risultati contrastanti PTEN –: ORR % inferiori rispetto ai PTEN+ (Nagata Y, Cancer Cell 2004) Nessuna differenza in outcome tra PTEN- e PTEN + (Gori S, Ann Oncol 2009) Setting neoadiuvante Espressione di PTEN non è associata a pCR (NOAH- Gianni L, ASCO 2008) Setting adiuvante PTEN-negatività non si correla ad una ridotta DFS nei gruppi trattati con Trastuzumab (Perez EA; ASCO 2011)

  43. HER2-positive breast cancer HER3 status

  44. HER3 status by immunohistochemistry in HER2-positive metastatic breast cancer patients treated with trastuzumab: correlation with clinical outcome.Gori S et al, TUMORI 2011 in press A B IHC expression of HER3 in HER2+ MBC (immunoperoxidase, 400 x) A. HER3–negative (positive tumour cells 50%) 30 pts B. HER3-positive (positive tumour cells >50%) 31 pts HER3 status by IHC was not significantly associated with clinical outcome

  45. HER3-negative status by IHC in HER2-positive MBC:longer OS and TTP A Gori S et al, TUMORI 2011 in press

  46. NOAH trial Gianni L, ASCO 2008

  47. Oltre lo stato di HER2- positività CONCLUSIONI 1. I tumori HER2+ non sono un gruppo omogeneo 2. Ad oggi, nei tumori HER2+, l’unico altro dato a disposizione utile a fini prognostici e terapeutici, è lo stato dei recettori ormonali

  48. THANK YOU !

More Related